A Single Arm Phase I-II Multicenter Trial With Avelumab Plus Autologous Dendritic Cell Vaccine to Determine Safety and Preliminary Efficacy of the Combination in Pre-treated Mismatch Repair-proficient (MSS) Metastatic Colorectal Cancer Patients.
Latest Information Update: 08 Apr 2023
At a glance
- Drugs Avelumab (Primary) ; Dendritic cell vaccines
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms AVEVAC
- 01 Apr 2023 Results assessing the safety, pharmacodynamics and anti-tumor effects of Avelumab plus autologous dendritic cells vaccine in heavily pre-treated mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer patients, published in the Cancer Immunology Immunotherapy.
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress
- 05 Oct 2020 Status changed from active, no longer recruiting to completed.